Management of Chronic Kidney Disease

Blood Pressure Management

The American College of Cardiology recommends a blood pressure target of <130/80 mm Hg for all patients with CKD, based on SPRINT trial evidence showing cardiovascular and mortality benefits with intensive BP control 1
The American College of Cardiology guidelines apply this lower target even in elderly patients (≥75 years), as SPRINT demonstrated benefits in frail elderly patients without increased harm 1
The American College of Cardiology suggests using standardized office BP measurement for monitoring 1

The American College of Cardiology and the Annals of Internal Medicine recommend initiating an ACE inhibitor or ARB as first-line antihypertensive therapy, titrating to the maximally tolerated dose 3, 4, 5
ACE inhibitors or ARBs provide both blood pressure control and nephroprotection in patients with proteinuria, even at relatively low levels 3, 4
The Kidney International guidelines suggest continuing ACE inhibitor/ARB therapy unless serum creatinine increases by more than 30% within 4 weeks, as modest increases up to 30% are expected and acceptable 5
The American College of Cardiology and the Annals of Internal Medicine advise against combining ACE inhibitor with ARB or direct renin inhibitor, as this increases risk of hyperkalemia, hypotension, and acute kidney injury without additional benefit 1, 3, 6

The Circulation guidelines indicate that 60% stenosis is below the threshold for hemodynamic significance (typically requires ≥70-80% stenosis) 2
The American College of Cardiology/American Heart Association guidelines suggest that revascularization may be considered for progressive CKD with bilateral RAS or RAS to a solitary kidney, but not for unilateral moderate stenosis 2

The Kidney International and Annals of Internal Medicine guidelines recommend restricting dietary sodium to <2 g/day (<90 mmol/day) to enhance blood pressure control and slow CKD progression 3, 5
The Annals of Internal Medicine suggests encouraging regular exercise (30 minutes, 5 times per week), smoking cessation if applicable, and maintaining a healthy body weight (BMI 20-25 kg/m²) 3
The Kidney International guidelines advise monitoring for hyperkalemia and metabolic acidosis, and using potassium-wasting diuretics or potassium binders if hyperkalemia develops, to allow continuation of ACE inhibitor/ARB therapy 5

The Annals of Internal Medicine recommends monitoring eGFR and proteinuria every 3-6 months given CKD stage 3a 4
The Kidney International and Praxis Medical Insights guidelines suggest checking serum creatinine, potassium, and bicarbonate 2-4 weeks after any medication changes 5, 6
The Annals of Internal Medicine defines progression as both a change in eGFR category AND ≥25% decline in eGFR 3, 4